Faculty Information

Present specialized field

BooK

Journal

Presentation

（Last updated : 2024-09-12 08:45:21）

Mikio Oka
Department Kawasaki Medical School Kawasaki Medical School, Department of Immuno-Oncology,

Position Professor with Special Assignment

■ Present specialized field

Respiratory medicine, Immunology

■ BooK

2019/03

Immune Surveillance and Biomarkers for Immune-checkpoint Therapy in Lung Cancer, 2018 RIKEN Annual Report

■ Journal

1.	2019/12/01	Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC.
2.	2018/09	A recurrent case of eosinophilic pneumonia with high IL-25 levels.
3.	2018/10	Deciduoid type malignant pleural mesothelioma: a case report
4.	2017/05	NY-ESO-1 protein cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by poly-ICLC
5.	2016/12	Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
6.	2017/03	NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
7.	2016/10	Pulmonary M. scrofulaceum disease showing false-positive response of anti-GPL core IgA antibody.
8.	2016/06	Development of two types of mite-allergen induced murine models of chronic ashtma with different sevrity.
9.	2015/09	Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients.
10.	2015/01	Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an anti-human CCR4 mAb (KM2760).
11.	2014/10	Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.
12.	2014/12	Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.
13.	2014/03	TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD).
14.	2014/04	Genetic variants of immunoglobulin g and k chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer
15.	2014/04	Increased levels of plasma galectin-9 in patients with influenza virus infection.
16.	2014/02	Vaccination With NY-ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY-ESO-1 Antigen
17.	2013/01	Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
18.	2012/09	Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
19.	2012/05	Possible regulatory role of galectin-9 on Ascaris suum-induced eosinophilic lung inflammation in mice.
20.	2011/12	A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
21.	2011/11	CD44 is critical for airway accumulation of antigen-specific Th2, but not Th1, cells induced by antigen challenge in mice.
22.	2024/06/28	Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer
23.	2024/02/07	Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study
24.	2023/09	Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
25.	2023/04/01	Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis
26.	2023/01/11	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
27.	2022/09/29	Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay
28.	2021/12/14	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab.
29.	2021/11	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors
30.	2021/11	Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
31.	2021/08	A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer
32.	2020/01/15	Thoracoscopic Findings in IgG4-related Pleuritis.
33.	2018/12	Biomarkers for differentiation of patients with asthma and chronic obstractive pulmonary disease
34.	2017/12	Possible Role of IL-25 in Eosinophilic Lung Inflammation in Patients with Chronic Eosinophilic Pneumonia.
35.	2017/07	Beneficial effects of Galectin-9 on allergen-specific sublingual immumotherapy in a Dermatophagoides farina-induced mouse model of chronic asthma.
36.	2017/04	Clinical analysis of military tuberculosis patients in our tertiary hospital.
37.	2016/11	Clinical analysis of pulmonary nontuberculous Mycobacterial disease complicated by lung cancer during the follow-up periods
38.	2016/02	A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
39.	2016/02	Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.
40.	2015/10	Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
41.	2015/08	Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia.
42.	2014/12	antibody immunotherapy in cancer
43.	2014/07	Lung auscultation and its significance
44.	2014/05	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma.
45.	2014/04	The exacerbation risk prediction by fractional exhaled nitric oxide in younger and elder children with bronchial asthma
46.	2014/02	Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients
47.	2013/12	Preventive effect of galectin-9 on double-stranded RNA-induced airway hyperresponsiveness in an exacerbation model of mite antigen-induced asthma in mice.
48.	2013/09	Step-down of budesonide/formoterol in early stages of asthma treatment leads to insufficient anti-inflammatory effect.
49.	2013/08	Critical role of interleukin-5 in the development of a mite antigen-induced chronic bronchial asthma model.
50.	2013/06	Clinical analysis of patients with pulmonary nontuberculous mycobacterial disease complicated by pneumothorax.
51.	2013/06	Mucoid impaction of the bronchi caused by Mycobacterium avium
52.	2013/05	Clinical analysis of pulmonary nontuberculous mycobacterial disease diagnosed as coincidental pulmonary infection due to Mycobacterium species
53.	2013/04	Serological assay by use of glycopeptidolipid core antigen Mycobacterium avium complex
54.	2013	Establishment of an asthma model by sensitization with mite antigen alone in C57BL/6J mice
55.	2012/11	Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
56.	2012/08	Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period.
57.	2012/05	Usefulness of tuberculin skin test and three interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis.
58.	2012	A case of platypnea orthodeoxia syndrome: a persistent history taking was the key to diagnose.
59.	2012	Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer.
60.	2012	Stereotactic body radiotherapy for lung tumors: Preliminary results from a single institution.
61.	2011/05	Pulmonary Mycobacterium massiliense disease with septicemia during immunosuppressive treatment.
62.	2011/05	Stability of sealed-bag samples for off-line measurement of fractional exhaled nitric oxide.
63.	2011/04	Outbreak of pertussis in a university laboratory
64.	2011/04	Outbreak of pertussis in a university laboratory.
65.	2011/04	Solitary pulmonary nodule due to Mycobacterium kansasii.
66.	2011/03	Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults.
67.	2011/02	Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age.
68.	2011/02	High serum arginase I levels in asthma: its correlation with high-sensitivity C-reactive protein.
69.	2011/01	Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A16 and UGT1A127 with severe neutropenia.
70.	2011	Impaired coronary flow reserve in obstructive sleep apnea and its improvement after continuous positive airway pressure therapy: a transthoracic Doppler echocardiographic study
71.	2011	Nutritional deficits in elderly smokers with respiratory symptoms that do not fulfill the criteria for COPD.
72.	2010/12	Enrichment of Foxp3+ CD4 Tregs in migrated T-cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6.
73.	2010/11	Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease.
74.	2010/10	Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor
75.	2010/10	Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia.
76.	2010/09	Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.
77.	2010/09	Rapid diagnosis of tuberculous pericarditis by ELISPOT assay.
78.	2010/03	Evaluation of false-positive reaction with ELISA for the detection of Chlamydophila pneumoniae-specific IgM antibody in adults.
79.	2010	Comparison of T-cell interferon-gamma release assays for Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis.
80.	2009/11	Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacterial disease.
81.	2009/11	Clinical usefulness of fluoro-2-deoxy-D-glucose PET in a case with multiple bone metastases of carcinoid tumor after ten years.
82.	2009/11	QuantiFERON TB-2G test for patients with active tuberculosis stratified by age groups.
83.	2009/10	Clinical evaluation of QuantiFERON TB-2G test in patients with healed pulmonary tuberculosis.
84.	2009/07	False negative results of QuantiFERON TB-2G test in patients with active tuberculosis.
85.	2009/06	A Phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer.
86.	2009/05	Clinical usefulness of QuantiFERON TB-2G test for the early diagnosis of pulmonary Mycobacterium kansasii disease.
87.	2009/05	Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity
88.	2009/04	Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice.
89.	2009/04	Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing.
90.	2009/04	Rosai-Dorfman disease presenting as a solitary mediastinal mass.
91.	2009/03	Clinical utility of a T cell-based assay in the diagnosis of extrapulmonary tuberculosis.
92.	2009/03	Rapid diagnosis of tuberculous pleuritis by a T-cell interferon-gamma release assay.
93.	2009/03	Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment.
94.	2009/02	Clinical evaluation of the T-SPOT.TB test for patients with indeterminate results on the QuantiFERON TB-2G test.
95.	2008/11	Clinical analysis of cases of empyema due to Streptococcus milleri group.
96.	2008/11	Long-term follow-up of the QuantiFERON TB-2G test for active tuberculosis disease.
97.	2008/10	Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.
98.	2008/08	An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow.
99.	2008/08	Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan.
100.	2008/08	Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD).
101.	2008/08	Mycoplasma pneumoniae pneumonia in the elderly.
102.	2008/06	Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: differentiation from multiple atypical adenomatous hyperplasia.
103.	2008/06	Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.
104.	2008/06	Rapid and simple diagnosis of Chlamydophila pneumoniae pneumonia by an immunochromatographic test for detection of immunoglobulin M antibodies.
105.	2008/05	Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis.
106.	2008/05	Comparison of serological tests for detection of immunoglobulin M antibodies to Chlamydophila pneumoniae.
107.	2008/04	Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization.
108.	2008/04	Clinical evaluation for diagnosis active TB disease and transitional change of two commercial blood tests.
109.	2008/03	Evaluation of enzyme-linked immunosorbent assay for Chlamydophila pneumoniae-specific immunoglobulin M in acute respiratory tract infection.
110.	2008/03	Pulmonary mucormycosis (Cunninghamella bertholletiae) with cavitation diagnosed using ultra-thin fibre-optic bronchoscopy.
111.	2008/03	Transitional change in the clinical features of pulmonary tuberculosis.
112.	2008/02	Usefulness of the QuantiFERON TB-2G test for the differential diagnosis of pulmonary tuberculosis.
113.	2008/01	Induction chemotharapy with cisplatin, vinorelbine, and mitomycin-C followed by surgery for patients with pathologic N2 non-small-cell lung cancer.
114.	2008	Macrolide-resistant Mycoplasma pneumoniae in patients with community-acquired pneumonia.
115.	2007/12	An indeterminate QuantiFERON TB-2G response for miliary tuberculosis, due to severe pancytopenia.
116.	2007/12	Clinical features of immunocompromised and nonimmunocompromised patients with pulmonary tuberculosis.
117.	2007/12	Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit.
118.	2007/11	Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients.
119.	2007/09	Pulmonary alveolar proteinosis with bilateral ground-glass opacities localized in subpleural areas.
120.	2007/09	Usefulness of QuantiFERON TB-2G, a diagnostic method for latent tuberculosis infection, in a contact investigation of health care workers.
121.	2007/08	Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multi-institutional phase II study.
122.	2007/06	Evaluation of the diagnostic usefulness of real-time PCR for detection of Chlamydophila pneumoniae in acute respiratory infections.
123.	2007/05	Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma.
124.	2007/05	Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.
125.	2007/01	A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease.
126.	2007/01	The usefulness of bronchoscopy for the diagnosis of pulmonary tuberculosis.
127.	2006/12	Inflammatory pseudotumor of the lung: clinicopathological analysis in seven adult patients.
128.	2006/10	Sibling cases of Mycobacterium avium complex disease associated with hematological disease.
129.	2006	A phase I trial of carboplatin and etoposide for elderly (>75 year-old) patients with small-cell lung cancer.
130.	2006	Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity.
131.	2006	BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
132.	2006	Both bronchial and vascular stenting followed by chemoradiotherapy for locally advanced non-small cell lung cancer.
133.	2006	Chronic necrotizing pulmonary aspergillosis as a complicationof pulmonary Mycobacterium avium complex disease.
134.	2006	Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis.
135.	2006	Evaluation of serological tests detecting Chlamydophila pneumoniae-specific immunoglobulin M antibody
136.	2006	Four cases of pulmonary Mycobacterium avium intracellulare complex presenting as a solitary pulmonary nodule and a review of other cases in Japan.
137.	2006	Phase II study of irinotecan combined with carboplatin in previously untreated small cell lung cancer.
138.	2006	Pulmonary Mycobacterium intracrellurare disease with a solitary pulmonary nodule detected at the onset of pneumothorax.
139.	2006	Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
140.	2006	Synchronous presentation of early-stage small cell carcinoma and adenocarcinoma in the same lung lobe.
141.	2006	The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations.
142.	2005/10	Coexistence of metastatic lung cancer and pulmonary tuberculosis diagnosed in the same cavity
143.	2005	Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study.
144.	2005	Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2 -mediated drug resistance.
145.	2005	Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
146.	2005	Infectious bulla of the lung caused by Mycobacterium intracellulare.
147.	2005	Lung adenocarcinoma required the differentiation for Wegener granulomatosis.
148.	2005	Outbreak of infection in long-term care facilities and an affiliated hospital.
149.	2005	Self-limiting pneumonia due to Chlamydia pneumoniae.
150.	2004/12	ヴェグナー肉芽腫症との識別を要した肺腺癌(Lung Adenocarcinoma Required the Differentiation from Wegener Granulomatosis)
151.	2004	A small outbreak of pulmonary tuberculosis in non-close contact patrons of a bar.
152.	2004	Autoimmunity to heat shock protein 40 in ulcerative colitis.
153.	2004	High-risk populations for nasal carriage of methicillin-resistant Staphylococcus aureus.
154.	2004	Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
155.	2004	Phase II study of irinotecan combined with carboplatin in previously untreated non-small cell lung cancer.
156.	2004	Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
157.	2004	The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
158.	2003	Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
159.	2003	Expression and functional analyses of breast cancer resistance protein in lung cancer.
160.	2003	Expression of heat shock protein (Hsp) 70 and Hsp 40 in colorectal cancer.
161.	2003	Expression of heat shock protein (Hsp) 70 and Hsp 40 in gastric cancer.
162.	2003	Expression of interleukin 6 and its receptor in human gastric and colorectal cancers.
Display 5 items
Display all(162)

■ Presentation

1.	2019/11/17	Immunological monitoring markers of clinical responses to anti-PD-1 therapy for non-small-cell lung cancer （Poster notice，General）
2.	2019/09/25	Serial antibody responses to XAGE1 and NY-ESO-1 antigens during anti-PD-1 therapy for non-small-cell lung cancer （Poster notice，General）
3.	2019/02/28	Serum NY-ESO-1 and XAGE1 Antibodies as Predictive Biomarkers in Anti-PD-1 Therapy for Non-Small-Cell Lung Cancer （Poster notice，General）
4.	2018/10/02	Serum antibody against NY-ESO-1 and XAGE1 predicts clinical responses to anti-PD-1 therapy in non-small-cell lung cancer. （Poster notice，General）
5.	2018/01/26	Clinical significance of humoral immunity against XAGE1 cancer-testis antigen in lung adenocarcinoma （Poster notice，General）
6.	2017/04/01	Immuno-inhibitory pathway, TIM-3/Galectin-9, in lung adenocarcinoma: clinical and in vitro analysis. （Poster notice，General）
7.	2017/04/01	The relationship between the UGT1A127 and UGT1A17 genetic polymorphisms and irinotecan-related toxicities in patients with lung cancer. （Poster notice，General）
8.	2016/09/25	Role of TIM-3/Galectin-9 pathway in lung adenocarcinoma. （Poster notice，General）
9.	2016/06/11	Galectin-9 enhances the effecf of allergen-specific sublingual immunotherapy in a Dermatophagoides farinae-induced mouse model of chronic asthma. （Speech，General）
10.	2016/06/11	A possible role of galectin-9 in the lung inflammation and fibrosis of patients with intersititial pneumonia （Speech，General）
11.	2016/09/03	Clinical evaluation of several biomarkers including IFN- for the diagnosis of tuberculosis infection. （Poster notice，General）
12.	2016/09/03	Clinical analysis of glycopeptidolipid core antigen IgA antibodies for cases in which it is difficult to obtain a definite diagnosis of Mycobacterium avium complex pulmonary disease. （Poster notice，General）
13.	2015/09/26	Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, （Poster notice，General）
14.	2015/09/26	Discriminant function for predicting survival of lung adenocarcinoma patients developed by using immune parameters of PD-L1,Gal-9, and XAGE1 expression on tumor cells and T cell infiltration score. （Poster notice，General）
15.	2015/09/26	Induction of galectin-9 production by viral infection in the lung. （Speech，General）
16.	2015/09/26	Clinical evaluation of diagnostic potential of several biomarkers for immunodiagnosis of tuberculosis infection including IGRAs (QFT and T-SPOT.TB) （Poster notice，General）
17.	2015/09/26	Clinical evaluation of glycopeptidolipid core antigen IgA antibodies for serodiagnosis of Mycobacterium avium complex pulmonary disease. （Poster notice，General）
18.	2015/04/17	Clinical effect of XAGE1(GAGED2a) antigen expression and antibody response in EGFR mutated and wild-type advanced lung adenocarcinoma （Speech，General）
19.	2012/03/31	Correlation of antibody and T-cell responses against XAGE-1b in NSCLC patients （Poster notice，General）
20.	2012/10/01	Immune response to XAGE-1b(GAGED2a)in NSCLC patients and its clinical relevance （Poster notice，General）
21.	2012/10/01	Treg depletion from PBMCs by treatment with defucosylated anti-human CCR4 mAb （Poster notice，General）
22.	2013/04/06	Immune response to XAGE-1b (GAGED2a) in NSCLC patients and its clinical relevance （Poster notice，General）
23.	2013/04/06	Depletion of Tregs from PBMCs by treatment with defucosylated anti-CCR4 mAb （Poster notice，General）
24.	2024/09/09	Serum NY-ESO-1 and XAGE1 antibodies are diagnostic and cancer-specific immunomonitoring markers in NSCLC （Poster notice，General）
25.	2024/05/15	Serum NY-ESO-1 and XAGE1 antibodies are potentially predictive and immunomonitoring markers of response to immune checkpoint therapy in non-small cell lung cancer （Speech，General）
26.	2023/09/20	Antibodies against tumor-associated antigens are associated with response to immune checkpoint therapy for non-small-cell lung cancer （Poster notice，General）
27.	2022/10/21	Development of automated immunoassay to detect serum biomarkers predicting response to immune checkpoint inhibitors in NSCLC （Poster notice，General）
28.	2022/08/06	Serum NY-ESO-1 and XAGE1 antibodies predict and monitor clinical responses to immune checkpoint therapy for NSCLC （Poster notice，General）
29.	2021/11/20	The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 monotherapy （Speech，General）
30.	2020/06/22	Development of a fully automated immunoassay system for detection of serum NY-ESO-1 and XAGE1 antibodies as biomarkers predicting the clinical efficacy of anti-PD-1 therapy （Poster notice，General）
31.	2020/06/22	Phase I study of XAGE1 peptide vaccine in patients with lung adenocarcinoma. （Poster notice，General）
32.	2017/10/17	Correlation of Clinical Response and XAGE1 Immunity in Lung Adenocarcinoma. （Poster notice，General）
33.	2017/10/17	Reviving Chemotherapy Sensityvity after Anti-CCR4 mAb (Mogamulizumab) Treatment in Lung Cancer Patients. （Poster notice，General）
34.	2017/09/10	Possible role of IL-25 in eosinophilic lung inflammation in patients with eosinophilic pneumonia. （Speech，General）
35.	2017/09/06	Reviving chemotherapy sensitivity after anti-CCR4 mAb (mogamulizumab) treatment in lung cancer patients. （Poster notice，General）
36.	2015/10/29	Psychological support of the lung cancer patients receiving chemotherapy （Poster notice，General）
37.	2014/10/05	Clinical effect of XAGE1 (GAGED2a) antigen expression and antibody response in EGFR mutated and wild-type advanced lung adenocarcinoma （Poster notice，General）
38.	2014/10/05	Increase of activated Tregs in TIL in lung cancer and in vitro depletion of Tregs by ADCC using anti-human CCR4 mAb (KM2760) （Poster notice，General）
39.	2014/09/06	Clinical evaluation of MIGRAs (IP-10 and MIG) including two IGRAs (QFT and T-SPOT) for the diagnosis of tuberculosis infection. （Poster notice，General）
40.	2014/06/07	Preventive effect of galectin-9 on double-stranded RNA-stranded RNA-induced airway hyperresponsiveness in an exacerbation model of mite antigen-induced murine asthma （Poster notice，General）
41.	2013/09/30	Depletion of Tregs from PBMCs by treatment with defucosylated anti-CCR4 mAb. （Poster notice，General）
42.	2013/09/30	Prolonged overall survival in XAGE-1b(GAGED2a) antibody positive NSCLC patients. （Poster notice，General）
43.	2013/09/07	Clinical analysisof patients with pulmonary nontuberculous mycobacterial disease complicated with pneumothorax （Poster notice，General）
44.	2013/09/07	Clinical evaluation of glycopeptidolipid core antigen IgA antibodies for serodiagnosis of mycobacterium avium complex pulmonary disease. （Poster notice，General）
45.	2013/06/23	Possible regulatory role of galectin-9 on Ascaris summ-induced eosinophilic lung inflammation in mice. （Speech，General）
46.	2012/09/01	Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan. （Poster notice，General）
47.	2012/09/01	Clinical evaluation of GPL core IgA antibodies for serodiagnosis of MAC pulmonary disease. （Poster notice，General）
48.	2012/09/01	Cough variant asthma may be a incipience of bronchial asthma. （Poster notice，General）
49.	2012/06/16	CD44 is critical for airway accumulation of Th2 cells induced by antigen challenge in mice. （Poster notice，General）
50.	2012/04/12	Thin-section CT imaging of patients with pulmonary mycobacterium infections: Comparison between Mycobacterium kansasii and Mycobacterium tuberculosis （Speech，General）
51.	2012/03/31	Immunogenicity of cancer/testis antigen XAGE-1d in patients with non-small-cell lung cancer (NSCLC) （Poster notice，General）
52.	2011/10/03	Correlation of Antibody and T Cell Responses Against XAGE-1b in NSCLC Patients （Poster notice，General）
53.	2011/10	Induction of CD8 T Cell Responses Restivted to Multiple HLA Class I Akkekes in a Cancer Patient by Immunization with a 20-Mer NY-ESO-1-1f (NY-ESO-1 91-110) Peptide （Poster notice，General）
54.	2011/07/03	Phase II study of Irinotecan and Cisplatin with Concurrent Split-course Radiotherapy in Limited-Disease Small-Cell Lung Cancer. （Poster notice，General）
55.	2011/06/11	Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia （Poster notice，General）
56.	2011/06/03	Fever during cancer chemotherapy: Analysis of 1,016 chemotherapy cycles （Poster notice，General）
57.	2011/04/22	非結核性抗酸菌症の診断に対する2つのinterferon-gamma release assay(IGRA)の臨床評価（Poster notice，General）
58.	2011/04/02	Enrichment of Foxp3+ CD4 Tregs in migrated T-cells to IL-6-and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6 （Poster notice，General）
59.	2011/04/02	XAGE-1b(GAGED2a) Immunity in Non-small-cell Lung Cancer （Poster notice，General）
60.	2010/10/08	Phase Ⅱ study of Irinotecan and Cisplatin with Concurrent Split-course Radiotherapy in Limited -Disease Small-Cell Lung Cancer. （Poster notice，General）
61.	2010/10/06	CD8 T-Cell Response in NY-ESO-1 F-Peptide Vaccinated Patients （Poster notice，General）
62.	2010/10/06	Spontaneous XAGE-1b Immunity in Patients with Non-Small-Cell Lung Cancer （Poster notice，General）
63.	2010/09/18	Clinical evaluation of two interferon-gamma release assay (IGRA) tests for immunocompromised patients. （Poster notice，General）
64.	2010/09/18	Comparative study of therapeutic effects of combined chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease. （Poster notice，General）
65.	2010/09/18	Desenstitization therapy for allergic reactions to antituberculous drugs. （Poster notice，General）
66.	2010/08/25	Enrichment of Foxp3+ CD4 Tregs in migrated T-cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. (*Young Investigator Award) （Poster notice，General）
67.	2010/04/17	Enrichment of Tregs in migrated T-cells to IL-6- and IL-8-expressing tumors through induction of CXCR1 by IL-6. （Poster notice，General）
68.	2010/04/17	Spontaneous immune responses against XAGE-1b in patients with non-small cell lung cancer (NSCLC). （Poster notice，General）
69.	2009/12/03	Enriched migration of Foxp3+ CD4 Tregs to IL-6 and IL-8-expressing tumor through CXCR1 induction by IL-6 （Poster notice，Panelist at Symposium/Workshop (Other)）
70.	2009/12/03	Spontaneous immune responses against XAGE-1b in patients with non-small-cell lung cancer (NSCLC) （Poster notice，Panelist at Symposium/Workshop (Other)）
71.	2009/11/14	A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer. （Poster notice，General）
72.	2009/11/14	Fever during cancer chemotherapy: analysis of 718 chemotherapy cycles. （Poster notice，General）
73.	2009/10/31	Macrolide-resistant Mycoplasma pneumoniae in patients with community-acquired pneumonia in Japan. （Poster notice，General）
74.	2009/10/31	Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing. （Poster notice，General）
75.	2009/10/03	Migration of Foxp3+ CD4 Tregs to IL-6 and IL-8 expressing tumor through CXCR1 induction （Speech，General）
76.	2009/10/01	XAGE-1b immunity in patients with non-small-cell lung cancer (NSCLC) （Speech，General）
77.	2009/09/20	A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer. （Poster notice，General）
78.	2009/09/12	Clinical evaluation of QuantiFERON TB-2G test for patients with active tuberculosis disease stratified by age groups. （General）
79.	2009/09/12	Clinical evaluation of QuantiFERON TB-2G test in patients with nontuberculous mycobacterial disease. （General）
80.	2009/09/12	Comparison of T-cell interferon-γ release assay to Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis. （General）
81.	2009/09/12	Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment. （Poster notice，General）
82.	2009/07/31	A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer. （Poster notice，General）
83.	2009/06/12	A Phase I study of Amrubicin and Carboplatin for Previously Untreated Patients with Extensive-Disease Small-Cell Lung Cancer （Speech，Panelist at Symposium/Workshop (Other)）
84.	2008/12/01	Antibody and CD4 T-cell response against XAGE-1b in lung cancer patients （Poster notice，Panelist at Symposium/Workshop (Other)）
85.	2008/10/28	Antibody and CD4 T-cell responses against XAGE-1b in lung cancer patients. （Poster notice，General）
86.	2008/10/28	Fever in patients receiving cancer chemotherapy. （Poster notice，General）
87.	2008/10/28	Pharmacokinetics of gefitinib predicts the antitumor activity for NSCLC patients: adding the analysis of EGFR-mutations. （Poster notice，General）
88.	2008/10/04	Asthma control test (ACT) problem and the complementary effect by peak flow rate (PEFR) measurement at outpatient department. （Poster notice，General）
89.	2008/10/04	Clinical utility of T-cell-based assay for the diagnosis of extrapulmonary tuberculosis （Poster notice，General）
90.	2008/10/04	Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice. （Poster notice，General）
91.	2008/10/03	UGT1A16 and UGT1A127 are associated with irinotecan-induced severe neutropenia in Japanese patients with NSCLC: Results of a randomized phase II trial of irinotecan combined with paclitaxel or gemcitabine. （Poster notice，General）
92.	2008/10/01	Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis. （Poster notice，General）
93.	2008/09/12	UGT1A16 and UGT1A127 are associated with irinotecan-induced severe neutropenia in Japanese patients with NSCLC. （Poster notice，General）
94.	2008/07/01	Rapid diagnosis of Chlamydia pneumoniae pneumonia by using an immunochromatographic test for the detection of immunoglobulin M antibodies. （Poster notice，General）
95.	2007/12	Clinical features of severe Mycoplasma pneumoniae in adults admitted to an intensive care unit （Poster notice，General）
96.	2007/12	Comparison of serological tests for detection of immunoglobulin M antibodies to Chlamydia pneumoniae （Speech，Panelist at Symposium/Workshop (Other)）
97.	2007/09/15	Clinical usefulness of exhaled breath temperature in asthma control. （Poster notice，General）
98.	2007/09/15	Comparison of the tuberculin skin test and two commercial blood tests for diagnosing active mycobacterium tubedrculosis infection and nontuberculous mycobacterium infection （Poster notice，General）
99.	2007/09/15	The accuracy of asthma control test (act™) inter linkage of asthma diary record. （Poster notice，General）
100.	2007/09/15	Usefulness of the QuantiFERON TB-2G test for the differential diagnosis of pulmonary tuberculosis （Poster notice，General）
101.	2007/09	Clinical evaluation of QuantuFERON TB-2G test for immunocompromised patients （Speech，General）
102.	2007/09	Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC) （Poster notice，General）
103.	2007/09	Randomized phase II trial of irinotecan combined with paclitaxel or gemcitabine in untreated advanced non-small cell lung cancer （Poster notice，General）
104.	2007/06	Phase II trial of irinotecan plus cisplatin with concurrent thoracic radiotherapy (TRT) in patients with previously untreated locally advanced non-small cell lung cancer (NSCLC) （Poster notice，General）
105.	2006/12	Clinical effect of combined therapy according to the guidelines for the treatment of pulmonary Mycobacterium avium complex disease. （Poster notice，General）
106.	2006/12	Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC). （Speech，General）
107.	2006/12	Pranlukast may reduce frequency of catching "common cold" in chronic ashmatics. （Poster notice，General）
108.	2006/12	Rapid diagnostic method of atypical pneumonia. （Poster notice，General）
109.	2006/12	Re-treatment with gefitinib in advanced lung adenocarcinoma patients: a retrospective analysis. （Poster notice，General）
110.	2006/09	A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. （Speech，General）
111.	2006/09	Clinical evaluation of a diagnostic method of tuberculosis infection, QuantiFERON TB-2G, for active tuberculosis and nontuberculous mycobacteriosis. （Poster notice，General）
112.	2006/09	Japanese guidelines for the management of community-acquired pneumonia :differentialdiagnosis of atypical pneumonia and bacterial pneumonia. （Speech，General）
113.	2006/09	Usefulness of a diagnostic method of tuberculosis infection, QuantiFERON TB-2G, in a contact investigation of medical staffs. （Poster notice，General）
114.	2006/06	A phase II study of vinorelbine (VNR) and carboplatin (CBDCA) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). （Abstract Only，General）
115.	2006/06	Japanese guidelines for the management of community-acquired pneumonia: clinical differentiation of atypical pneumonia. （Speech，General）
116.	2006/06	Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC) （Speech，General）
117.	2005/09	Clinical features of pulmonary Mycobacterium avium intracellulare complex disease with a solitary pulmonary nodule in Japan. （Poster notice，General）
118.	2005/09	Current studies of patients discharging Mycobacterium tuberculosis after admission to Kawasaki Medical School Hospital. （Poster notice，General）
119.	2005/09	Japanese guidelines for the management of community-acquired pneumonia: differential diagnosis of atypical pneumonia and bacterial pneumonia. （Speech，General）
120.	2005/09	Pulmonary aspergillosis complicated by cavitary lesion formed by pulmonary Mycobacterium avium complex disease. （Speech，General）
121.	2004/11	Phase II study of irinotecan (CPT-11) andcisp latin (CDDP) with concurrent split-course thoracic radiotherapy (TRT) inlocally advanced stage III non-small cell lung cancer (NSCLC). （Poster notice，General）
122.	2004/06	Elderly (>=75) small-cell lung cancer (SCLC)chemotherapy: a phase I study of carboplatin (CBDCA) and etoposide (vp-16). （Poster notice，General）
123.	2004/06	Phase I study of gemcitabine (GEM) andcarboplat in (CBDCA) in advanced non-small cell lung cancer (NSCLC). （Poster notice，General）
124.	2004/06	Phase II study of irinotecan (CPT-11) andcisplatin (CDDP) with concurrent split-course thoracic radiotherapy (TRT) instage III non-small cell lung cancer (NSCLC). （Abstract Only，General）
125.	2003	Antiproliferative effects of the histone deacetylase inhibitor FR901228 on adult T-cell leukemia cell lines. （Poster notice，General）
126.	2003	Expression of breast cancer resisitance protein depends on the methylation status of its promoter region in lung cancer cells （Poster notice，General）
127.	2003	Gefitinib ('Iressa', ZD1839) inhibits topotecan-efflux in small-cell lung cancer cells overexpressing breast cancer resistance protein (BCRP/ABCG2) （Poster notice，General）
128.	2003	Phase I study of vinorelbine (VNR) and weekly irinotecan (CPT-11) as first line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). （Poster notice，General）
129.	2003	Pulmonary damage during gefitinib monotherapy in patients with non-small cell lung cancer. （Poster notice，General）
130.	2003	Pulmonary damage during gefitinib monotherapy in patients with non-small cell lung cancer. （Poster notice，General）
131.	2003	Survey of practical medicine for patients with unresectable non-small cell lung cancer in Nagasaki, Japan. （Abstract Only）
Display 5 items
Display all(131)